PTC THERAPEUTICS, INC.
PTC Therapeutics (PTCT) reported Q2 2026 revenue of $360.52M and net income of $83.5M, and raised its full-year 2026 total revenue outlook to $1.18B to $1.28B. The company also appointed Hege Sollie-Zetlmayer to its board. The update may affect investor views on profitability and guidance.
Klein Matthew B. (CHIEF EXECUTIVE OFFICER) sold 10,292 shares of PTC THERAPEUTICS, INC. (PTCT) at $68.57 ($0.71M total) on 2026-08-04 under a Rule 10b5-1 trading plan.
Simply Wall St reports PTC Therapeutics (PTCT) shares fell nearly 10% after Q2 2026 results. The company posted Q2 revenue of about $360.5m vs $178.9m a year earlier, and moved to basic EPS of about $1.01 from a loss. Sephience generated $151m product revenue; cash was $2.23b.
Over the past 7 days, alphai's AI scored 1 news story mentioning PTCT (PTC THERAPEUTICS, INC.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent PTCT coverage spans earnings and insider activity.
In the last 30 days, PTCT insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($986K). The most active reporter was Gravier Pierre, CHIEF FINANCIAL OFFICER, with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Profit beat plus higher FY revenue guidance likely supports near-term upside momentum, but the article flags ongoing concentration and Translarna regulatory risk.
This is a routine insider sale disclosure, not a new fundamental catalyst, but it can slightly affect near-term sentiment.
The article frames a sharp earnings inflection (loss to profit) versus persistent launch concentration and pipeline/regulatory timing risks.
The earnings beat plus raised 2026 revenue outlook is a direct fundamental re-rating catalyst for PTCT, though execution and international reimbursement timing remain key risks.
The company’s 2026 revenue range sets a clear consensus anchor and defines upside/downside expectations for PTCT’s forward sales trajectory.
alphai scores every news story that mentions PTCT with an AI model for sentiment and relevance, and aggregates insider trades from PTC THERAPEUTICS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
PTC Therapeutics (PTCT) reported Q2 2026 revenue of $360.52M and net income of $83.5M, and raised its full-year 2026 total revenue outlook to $1.18B to $1.28B. The company also appointed Hege Sollie-Zetlmayer to its board. The update may affect investor views on profitability and guidance.
5 min readKlein Matthew B. (CHIEF EXECUTIVE OFFICER) sold 10,292 shares of PTC THERAPEUTICS, INC. (PTCT) at $68.57 ($0.71M total) on 2026-08-04 under a Rule 10b5-1 trading plan.
2 min readSimply Wall St reports PTC Therapeutics (PTCT) shares fell nearly 10% after Q2 2026 results. The company posted Q2 revenue of about $360.5m vs $178.9m a year earlier, and moved to basic EPS of about $1.01 from a loss. Sephience generated $151m product revenue; cash was $2.23b.
6 min readNasdaq sees best day in over a month as Microsoft breathes life back into AI trade PTC Therapeutics reported stronger-than-expected second-quarter 2026 results, with earnings of $0.92 a share on revenue of $361 million, well ahead of Wall Street’s forecast for $0.32 a share and $293.1 million in sales. The company said the quarter reflected record revenue, led by Sephience, and raised its full-year outlook.
4 min read(PTCT) PTC Therapeutics Expects Full Year 2026 Revenue Range $1.18B - $1.28B, vs. FactSet Est of $1.18B Published on 07/30/2026 at 04:48 pm EDT | Market Closed - Other stock markets | 5-day change | 1st Jan Change | || | 75.52 USD | +1.38% | -3.67% | -0.58% | | Jul. 30 | PTC Q2 Swings to Profit, Revenue Rises; Ups Guidance | MT | | Jul. 30 | PTC Therapeutics, Inc.
2 min readPTC Therapeutics, Inc. (NASDAQ: PTCT) posts Q2 2026 profit, Phase 3 HD trial PTC Therapeutics, Inc. reported strong Q2 2026 results, with total revenues of $360.5 million, up from $178.9 million a year earlier. Growth was driven by net product revenue of $238.8 million and collaboration and license revenue of $50.6 million, including a $50.0 million milestone from Novartis for Huntington’s disease candidate votoplam. Royalty revenue contributed $71.1 million.
6 min readPTC Therapeutics (NASDAQ: PTCT) raises 2026 revenue guidance after strong Q2 Rhea-AI Filing Summary PTC Therapeutics reported strong second-quarter 2026 results, with total revenue of $361 million, including $239 million of product revenue. Sephience generated $151 million of Q2 2026 revenue and had 1,647 patients on commercial therapy worldwide as of June 30, 2026.
4 min readPTC THERAPEUTICS, INC. (PTCT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tmb-20260728xex99d1.htm EX-99.1 Exhibit 99.1 PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results – Robust Q2 performance with total revenue of $361 million, including $239 million of product revenue – – Full-year 2026 expec
6 min readPTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results Rhea-AI Summary PTC Therapeutics (NASDAQ: PTCT) reported Q2 2026 total revenue of $360.5 million, including $238.8 million in net product revenue and $71.1 million in Evrysdi royalties. Sephience™ generated $151.3 million with 1,647 patients on commercial therapy worldwide.
6 min readRaymond James issued an earnings preview for seven commercial-stage biopharma firms ahead of Q2 2026 results. It highlighted Insmed (INSM) launch growth, United Therapeutics (UTHR) Tyvaso revenue of about $480M-$490M, Jazz (JAZZ) potential beat, Ionis (IONS) Tryngolza value, PTC (PTCT) $150M-$160M Q2 sales, Tonix (TNXP) access expansion, and Milestone (MIST) Cardamyst trajectory.
2 min read